Movatterモバイル変換


[0]ホーム

URL:


SG10201906716QA - Mir-92 inhibitors and uses thereof - Google Patents

Mir-92 inhibitors and uses thereof

Info

Publication number
SG10201906716QA
SG10201906716QASG10201906716QASG10201906716QASG10201906716QASG 10201906716Q ASG10201906716Q ASG 10201906716QASG 10201906716Q ASG10201906716Q ASG 10201906716QASG 10201906716Q ASG10201906716Q ASG 10201906716QASG 10201906716Q ASG10201906716Q ASG 10201906716QA
Authority
SG
Singapore
Prior art keywords
mir
inhibitors
therapeutic
activity
subject
Prior art date
Application number
SG10201906716QA
Inventor
Christina Marie Dalby
Corrie Lynn Gallant-Behm
Aimee Jackson
Kathryn Hutnick
Anita Seto
Original Assignee
Miragen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miragen Therapeutics IncfiledCriticalMiragen Therapeutics Inc
Publication of SG10201906716QApublicationCriticalpatent/SG10201906716QA/en

Links

Classifications

Landscapes

Abstract

MIR-92 INHIBITORS AND USES THEREOF The present invention provides oligonucleotide inhibitors of miR-92 and methods of using said inhibitors for inhibiting the function and/or activity of miR-92 in a subject in need thereof. The present invention also provides methods for evaluating or monitoring the efficacy of a therapeutic for promoting wound healing and selecting a subject for treatment with a therapeutic that modulates miR- 92 function and/or activity. Fig.1
SG10201906716QA2015-01-202016-01-20Mir-92 inhibitors and uses thereofSG10201906716QA (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US201562105546P2015-01-202015-01-20

Publications (1)

Publication NumberPublication Date
SG10201906716QAtrue SG10201906716QA (en)2019-08-27

Family

ID=56407360

Family Applications (2)

Application NumberTitlePriority DateFiling Date
SG10201906716QASG10201906716QA (en)2015-01-202016-01-20Mir-92 inhibitors and uses thereof
SG11201705907XASG11201705907XA (en)2015-01-202016-01-20Mir-92 inhibitors and uses thereof

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
SG11201705907XASG11201705907XA (en)2015-01-202016-01-20Mir-92 inhibitors and uses thereof

Country Status (13)

CountryLink
US (3)US9885042B2 (en)
EP (1)EP3247716A4 (en)
JP (1)JP2018503646A (en)
KR (1)KR20170103841A (en)
CN (1)CN107636003A (en)
AU (1)AU2016209386A1 (en)
BR (1)BR112017015618A2 (en)
CA (1)CA2974189A1 (en)
EA (1)EA201791644A1 (en)
HK (2)HK1249108A1 (en)
MX (1)MX2017009427A (en)
SG (2)SG10201906716QA (en)
WO (1)WO2016118612A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US9388408B2 (en)2012-06-212016-07-12MiRagen Therapeutics, Inc.Oligonucleotide-based inhibitors comprising locked nucleic acid motif
SG10201906716QA (en)2015-01-202019-08-27Miragen Therapeutics IncMir-92 inhibitors and uses thereof
AU2017368050A1 (en)2016-11-292019-06-20Puretech Lyt, Inc.Exosomes for delivery of therapeutic agents
AU2018255346B2 (en)2017-04-192024-05-02Capricor, Inc.Methods and compositions for treating skeletal muscular dystrophy
WO2019126068A1 (en)2017-12-202019-06-27Cedars-Sinai Medical CenterEngineered extracellular vesicles for enhanced tissue delivery
WO2019152549A1 (en)2018-02-052019-08-08Cedars-Sinai Medical CenterMethods for therapeutic use of exosomes and y-rnas
CN110484537B (en)*2019-09-022021-07-27中国水产科学研究院淡水渔业研究中心miR-92 accelerant and preparation method and application of miR-92 accelerant and injection thereof
KR20240028486A (en)*2021-07-012024-03-05세다르스-신나이 메디칼 센터 Formulations for oral delivery of nucleic acids

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6231881B1 (en)1992-02-242001-05-15Anton-Lewis UsalaMedium and matrix for long-term proliferation of cells
US5981505A (en)1993-01-261999-11-09The Trustees Of The University Of PennsylvaniaCompositions and methods for delivery of genetic material
WO1995003843A1 (en)1993-07-301995-02-09The Regents Of The University Of CaliforniaEndocardial infusion catheter
US5837533A (en)1994-09-281998-11-17American Home Products CorporationComplexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en)1994-12-091998-11-24Genzyme CorporationCationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
JP3756313B2 (en)1997-03-072006-03-15武 今西 Novel bicyclonucleosides and oligonucleotide analogues
US6770748B2 (en)1997-03-072004-08-03Takeshi ImanishiBicyclonucleoside and oligonucleotide analogue
US6416510B1 (en)1997-03-132002-07-09Biocardia, Inc.Drug delivery catheters that attach to tissue and methods for their use
US6217900B1 (en)1997-04-302001-04-17American Home Products CorporationVesicular complexes and methods of making and using the same
WO1999001579A1 (en)1997-07-011999-01-14Isis Pharmaceuticals, Inc.Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6794499B2 (en)1997-09-122004-09-21Exiqon A/SOligonucleotide analogues
US6749617B1 (en)1997-11-042004-06-15Scimed Life Systems, Inc.Catheter and implants for the delivery of therapeutic agents to tissues
HRP20000751A2 (en)1998-05-262001-12-31Icn PharmaceuticalsNovel nucleosides having bicyclic sugar moiety
US6833361B2 (en)1998-05-262004-12-21Ribapharm, Inc.Nucleosides having bicyclic sugar moiety
WO2000056916A2 (en)1999-03-182000-09-28Exiqon A/SDetection of mutations in genes by specific lna primers
AU7406600A (en)1999-10-042001-05-10Exiqon A/SA method of increasing the specificity of oxy-lna oligonucleotides
AU2001293687A1 (en)2000-10-042002-04-15Cureon A/SImproved synthesis of purine locked nucleic acid analogues
WO2003029459A2 (en)2001-09-282003-04-10MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.Micro-rna molecules
CA2487274A1 (en)2002-05-062003-11-13Nucleonics Inc.Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
US20080214437A1 (en)2002-09-062008-09-04Mohapatra Shyam SMethods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
AU2003281969B2 (en)2002-11-182011-01-27Roche Innovation Center Copenhagen A/SAmino-LNA, thio-LNA and alpha-L-oxy-LN
EP2530157B1 (en)2003-07-312016-09-28Regulus Therapeutics Inc.Oligomeric compounds and compositions for use in modulation of miRNAs
WO2005017145A1 (en)2003-08-132005-02-24Japan Biological Informatics ConsortiumMethod of identifying or presuming gene under regulation regulated by functional rna and method of using the same
EP1713938A2 (en)2004-02-092006-10-25Thomas Jefferson UniversityDIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
WO2005078096A2 (en)2004-02-092005-08-25University Of MassachusettsDual functional oligonucleotides for use in repressing mutant gene expression
AU2005214904B2 (en)2004-02-132011-07-21Rockefeller UniversityAnti-microRNA oligonucleotide molecules
BRPI0508073A (en)2004-02-262007-07-17Kardia Pty Ltd V method and apparatus for substantially isolating cardiac circulation from systemic circulation apparatus for perfusing the heart with a therapeutic agent, obstruction catheter for obstructing flow between a main vessel and one or more branched vessels, method for administering a therapeutic agent to the heart and support structure percutaneously manageable to maintain coronary sinus patency
US20070203445A1 (en)2004-02-262007-08-30V-Kardia Pty LtdIsolating cardiac circulation
US7722596B2 (en)2004-02-262010-05-25Osprey Medical, Inc.Regional cardiac tissue treatment
EP2290068A3 (en)2004-05-282012-01-04Asuragen, Inc.Methods and compositions involving microRNA
EP2284265B1 (en)2004-11-122015-01-07Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
US9550990B2 (en)2004-12-102017-01-24Ionis Pharmaceuticals, Inc.Regulation of epigenetic control of gene expression
US20060185027A1 (en)2004-12-232006-08-17David BartelSystems and methods for identifying miRNA targets and for altering miRNA and target expression
US20070099196A1 (en)2004-12-292007-05-03Sakari KauppinenNovel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
US8071306B2 (en)2005-01-252011-12-06Merck Sharp & Dohme Corp.Methods for quantitating small RNA molecules
US7404969B2 (en)2005-02-142008-07-29Sirna Therapeutics, Inc.Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2006089340A2 (en)2005-02-232006-08-31V-Kardia Pty LtdPolynucleotide delivery to cardiac tissue
WO2006111512A1 (en)2005-04-192006-10-26Basf Plant Science GmbhImproved methods controlling gene expression
CN101287834B (en)2005-05-272016-11-09圣拉法埃莱医院有限公司 Gene carrier
EP1904111A4 (en)2005-06-032009-08-19Univ Johns Hopkins COMPOSITIONS AND METHODS FOR DECREASING MICROARN EXPRESSION FOR THE TREATMENT OF NEOPLASIA
WO2007031333A2 (en)2005-09-152007-03-22Novosom AgImprovements in or relating to amphoteric liposomes
EP1969125B1 (en)2005-12-122012-06-13The University of North Carolina At Chapel HillMicrornas that regulate muscle cell proliferation and differentiation
US8129515B2 (en)2006-01-272012-03-06Isis Pharmaceuticals, Inc.Oligomeric compounds and compositions for the use in modulation of microRNAs
CA2649045C (en)2006-04-032019-06-11Santaris Pharma A/SPharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2436783B1 (en)2006-07-132013-09-11The Ohio State University Research FoundationMIR-103-2 for diagnosing poor survival prognosis colon adenocarcinoma.
US8466117B2 (en)2006-07-282013-06-18The Johns Hopkins UniversityCompositions and methods for modulating angiogenesis
CA2659364C (en)2006-08-012017-08-22Board Of Regents Of The University Of Texas SystemIdentification of a micro-rna that activates expression of .beta.-myosin heavy chain
WO2008042231A2 (en)2006-09-292008-04-10Children's Medical Center CorporationCompositions and methods for evaluating and treating heart failure
US8906870B2 (en)2006-10-092014-12-09Julius-Maximilians-Universitaet WuerzbergMicroRNA (miRNA) for the diagnosis and treatment of heart diseases
WO2008147430A2 (en)2006-10-112008-12-04Nucleonics, Inc.Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
CA2681568C (en)2006-11-232019-01-08Querdenker ApsOligonucleotides for modulating target rna activity
WO2008070082A2 (en)2006-12-042008-06-12The Johns Hopkins UniversityStem-progenitor cell specific micro-ribonucleic acids and uses thereof
CN102604951A (en)2006-12-142012-07-25诺瓦提斯公司Compositions and methods for treating muscular and cardiovascular disorders
US20090137504A1 (en)2006-12-212009-05-28Soren Morgenthaler EchwaldMicrorna target site blocking oligos and uses thereof
EP2113567B1 (en)2006-12-212019-04-03QIAGEN GmbHMicroRNA target site blocking oligos and uses thereof
WO2008113832A2 (en)2007-03-222008-09-25Santaris Pharma A/SSHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
WO2008131191A2 (en)2007-04-202008-10-30Amgen Inc.Nucleic acids hybridizable to micro rna and precursors thereof
JP5637533B2 (en)2007-05-232014-12-10ジーイー ヘルスケア ダーマコン,インク. Micro-RNA scaffold and non-naturally occurring micro-RNA
WO2009004632A2 (en)2007-07-052009-01-08Yeda Research And Development Co. Ltd.Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation
JP2010533503A (en)2007-07-182010-10-28ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト Differential expression of microRNA in contrast between human non-failing heart and human failing heart
CN101808649B (en)2007-07-312014-05-21得克萨斯系统大学董事会 MicroRNAs controlling myosin expression and muscle fiber identity
EP2192925A4 (en)2007-08-232013-04-03Keren PharmaceuticalsTargeting rna with external guide sequences
US8455199B2 (en)2007-09-142013-06-04The Ohio State University Research FoundationMicroRNA expression in human peripheral blood microvesicles and uses thereof
DK2623599T3 (en)2007-10-042019-04-08Roche Innovation Ct Copenhagen As Micromirers
WO2009058818A2 (en)2007-10-292009-05-07The Board Of Regents Of The University Of Texas SystemCompositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
DE102007052114B4 (en)2007-10-302011-01-05T2Cure Gmbh Method for modulating the function, growth or differentiation of a cell
CN101424640B (en)2007-11-022012-07-25江苏命码生物科技有限公司 Detection method of microribonucleic acid in serum, reagent kit for detection, biochip and its production and application method
CN101951924B (en)2007-11-092015-06-24得克萨斯系统大学董事会Micro-RNAs of the MIR-15 family modulate cardiomyocyte survival and cardiac repair
WO2009075882A2 (en)*2007-12-112009-06-18Coda Therapeutics, Inc.Impaired wound healing compositions and treatments
WO2009088786A1 (en)2007-12-312009-07-16Nanocor Therapeutics, Inc.Rna interference for the treatment of heart failure
EP2096171A1 (en)2008-02-272009-09-02Julius-Maximilians-Universität WürzburgMicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
WO2009114681A2 (en)2008-03-132009-09-17Dharmacon, Inc.Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy
US20090326049A1 (en)2008-04-042009-12-31Alexander AristarkhovBlocking oligos for inhibition of microrna and sirna activity and uses thereof
CA2726052A1 (en)2008-06-042009-12-10The Board Of Regents Of The University Of Texas SystemModulation of gene expression through endogenous small rna targeting of gene promoters
WO2009151600A2 (en)2008-06-102009-12-17Tufts UniversitySmad proteins control drosha-mediated mirna maturation
DK2310505T3 (en)2008-06-302017-10-16Roche Innovation Ct Copenhagen As ANTIDOT oligomers
CN101386848A (en)2008-08-122009-03-18南京大学 Microribonucleic acid contained in cell microparticles and its preparation research method and application
WO2010039543A2 (en)2008-09-232010-04-08Traversa Therapeutics, Inc.Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
WO2010048585A2 (en)2008-10-242010-04-29Isis Pharmaceuticals, Inc.Oligomeric compounds and methods
US20100249214A1 (en)2009-02-112010-09-30Dicerna PharmaceuticalsMultiplex dicer substrate rna interference molecules having joining sequences
KR20110128838A (en)2009-02-042011-11-30보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 Dual Targeting of MIR-208 and MIR-499 in the Treatment of Heart Disease
US20110086348A1 (en)2009-02-192011-04-14The Cleveland Clinic FoundationMethod for assessing heart disease
CN102459301B (en)2009-05-052016-01-20米拉根医疗公司lipophilic polynucleotide conjugates
MX2011012418A (en)2009-05-202012-07-20Univ TexasIdentification of micro-rnas involved in post-myocardial infarction remodeling and heart failure.
MX2011013176A (en)2009-06-082012-04-30Miragen TherapeuticsCHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS.
WO2011017408A1 (en)*2009-08-052011-02-10The Ohio State University Research FoundationAnti-mir-1 therapy for wound healing
AU2010294197C9 (en)2009-09-102018-09-13Velin-Pharma A/SMethod for the preparation of micro-RNA and its therapeutic application
US9364495B2 (en)2009-10-202016-06-14Roche Innovation Center Copenhagen A/SOral delivery of therapeutically effective LNA oligonucleotides
US8592151B2 (en)2009-11-172013-11-26Musc Foundation For Research DevelopmentAssessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids
US20130109738A1 (en)2010-02-242013-05-02The Board Of Trustees Of The Leland Stanford Junior UniversityControl of Cardiac Growth, Differentiation and Hypertrophy
WO2011117353A1 (en)2010-03-242011-09-29Mirrx Therapeutics A/SBivalent antisense oligonucleotides
EP2371370A1 (en)2010-04-012011-10-05Johann Wolfgang Goethe-Universität Frankfurt am MainAntagonists of miRNA-29 expression and their use in the prevention and treatment of aortic aneurysms and atherosclerotic plaque destabilization
US9821009B2 (en)2010-04-132017-11-21Jiangsu Mingma Biotech Co., Ltd.Method for modulating microRNA content in living beings and the use thereof
WO2011131354A1 (en)2010-04-202011-10-27Febit Holding GmbhComplex mirna sets as novel biomarkers for an acute coronary syndrome
WO2011139911A2 (en)2010-04-292011-11-10Isis Pharmaceuticals, Inc.Lipid formulated single stranded rna
EP2580328A2 (en)2010-06-112013-04-17Cellartis ABMicrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types
ITMI20101089A1 (en)2010-06-162011-12-17Istituto Naz Di Genetica Molecolare Ingm MICRO-RNA EXPRESSION PROFILES IN THE PERIPHERAL BLOOD FOR MONITORING THE IMMUNE SYSTEM
WO2012006181A2 (en)2010-06-292012-01-12Mount Sinai School Of MedicineCompositions and methods for inhibiting oncogenic micrornas and treatment of cancer
US9987309B2 (en)2010-07-082018-06-05Duke UniversityDirect reprogramming of cells to cardiac myocyte fate
US20130137753A1 (en)2010-08-032013-05-30University Of South AlabamaMethods and compositions for the diagnosis and treatment of breast cancer
EP2603592A2 (en)2010-08-132013-06-19The University Court of the University of GlasgowTherapeutic uses of microvesicles and related micrornas
US9243246B2 (en)2010-08-242016-01-26Sirna Therapeutics, Inc.Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
AU2011302152B2 (en)2010-09-152015-06-11Alnylam Pharmaceuticals, Inc.Modified iRNA agents
JP5995855B2 (en)2010-11-052016-09-21ミラゲン セラピューティクス,インコーポレイテッド Base-modified oligonucleotide
EP2638158A4 (en)*2010-11-112015-07-15Univ Miami COMPOSITIONS, CELLS, KITS AND METHODS FOR AUTOLOGOUS STEM CELL THERAPY
BR112013012319A2 (en)2010-12-152019-09-24Miragen Therapeutics micro rna inhibitors comprising blocked nucleotides
WO2012149646A1 (en)2011-05-052012-11-08Sunnybrook Research InstituteMirna inhibitors and their uses
EP2763703B1 (en)2011-10-062018-02-14Miragen Therapeutics, Inc.Control of whole body energy homeostasis by microrna regulation
GB201117482D0 (en)2011-10-112011-11-23Univ DundeeTargetiing of miRNA precursors
EP2584040A1 (en)2011-10-172013-04-24Pharmahungary 2000 Kft.Compounds for treatment of ischemic injury
ES2745373T3 (en)2011-10-182020-03-02Dicerna Pharmaceuticals Inc Cationic amine lipids and their use
JP2015502365A (en)2011-12-122015-01-22オンコイミューニン,インコーポレイティド In vivo delivery of oligonucleotides
US20140356459A1 (en)2011-12-152014-12-04Oncostamen S.R.L.Micrornas and uses thereof
EP2604690A1 (en)2011-12-152013-06-19Oncostamen S.r.l.MicroRNAs and uses thereof
FR2984358A1 (en)2011-12-162013-06-21Genethon METHODS FOR THE DIAGNOSIS OF MUSCLE DYSTROPHIES
US9163235B2 (en)2012-06-212015-10-20MiRagen Therapeutics, Inc.Inhibitors of the miR-15 family of micro-RNAs
US9388408B2 (en)2012-06-212016-07-12MiRagen Therapeutics, Inc.Oligonucleotide-based inhibitors comprising locked nucleic acid motif
EP2759595B1 (en)*2013-01-242016-09-14Pierre Fabre Médicament S.A.S.Composition comprising an encapsulated antagomir
US20160251720A1 (en)2013-11-012016-09-01The Trustees Of Columbia University In The City New YorkMicroRNA PROFILES IN HEART FAILURE: METHODS AND SYSTEMS FOR DETECTION AND USE
SG10201906716QA (en)2015-01-202019-08-27Miragen Therapeutics IncMir-92 inhibitors and uses thereof
CN107683341A (en)2015-05-082018-02-09新加坡科技研究局 Methods for the diagnosis and prognosis of chronic heart failure
EP3601565A4 (en)2017-03-252021-01-06Miragen Therapeutics, Inc.Mir-92 inhibitors for treatment of heart failure

Also Published As

Publication numberPublication date
SG11201705907XA (en)2017-08-30
EP3247716A4 (en)2018-10-17
WO2016118612A2 (en)2016-07-28
EA201791644A1 (en)2018-01-31
KR20170103841A (en)2017-09-13
US20160208258A1 (en)2016-07-21
HK1247617A1 (en)2018-09-28
US10280422B2 (en)2019-05-07
WO2016118612A3 (en)2016-08-25
CN107636003A (en)2018-01-26
BR112017015618A2 (en)2018-04-10
AU2016209386A1 (en)2017-08-03
MX2017009427A (en)2017-10-02
WO2016118612A8 (en)2017-08-31
US20190194662A1 (en)2019-06-27
HK1249108A1 (en)2018-10-26
US9885042B2 (en)2018-02-06
US20180237779A1 (en)2018-08-23
JP2018503646A (en)2018-02-08
CA2974189A1 (en)2016-07-28
EP3247716A2 (en)2017-11-29

Similar Documents

PublicationPublication DateTitle
SG10201906716QA (en)Mir-92 inhibitors and uses thereof
PH12019501575A1 (en)ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
IL273824A (en)Methods of using ehmt2 inhibitors in treating or preventing blood disorders
MX382902B (en) NOTH PATHWAY INHIBITOR IN COMBINATION WITH AN IMMUNOTHERAPEUTIC AGENT FOR USE IN THE TREATMENT OF CANCER.
HK1252693A1 (en)Inhibitors of egfr and methods of use thereof
PL3675953T3 (en)Devices and methods for contacting living tissue
PH12017500621A1 (en)Triazolopyrazinones as pde1 inhibitors
MX2017000307A (en)Treatment of leukemia with histone deacetylase inhibitors.
SG10201808940WA (en)Nox inhibitor and nfкb inhibitor containing methoxyflavone
PH12016500140A1 (en)Heterobicycloaryl rorc2 inhibitors and methods of use thereof
IL258500A (en)Combination therapy with glutaminase inhibitors and immuno-oncology agents
PH12019501373A1 (en)Methods of treating cochlears synaptopathy
PH12017501990B1 (en)Imidazopyrazinones as pde1 inhibitors
ZA201705561B (en)Kv1.3 inhibitors and their medical application
MA40364A (en)Combination therapy for treatment of cancer
GB202011900D0 (en)Methods for managing behavioral treatment therapy and devices thereof
MX2016010168A (en)Hexahydrofuropyrroles as pde1 inhibitors.
WO2014045126A3 (en)Treatment of pain by inhibition of usp5 de-ubiquitinase
ZA201705676B (en)Kv1.3 inhibitors and their medical application
GEP20197038B (en)Combination of at least one protease inhibitor and at least one active principle for use in the prevention and/or treatment of skin lesions

[8]ページ先頭

©2009-2025 Movatter.jp